[Recurrent esophageal cancer with complete response to TS-1 chemotherapy].

Abstract

An 80-year-old man was admitted to our hospital for treatment of recurrent esophageal cancer in December, 2004. He was diagnosed as having esophageal cancer of stage IVa (T2N4M0) in October, 2002, and he received chemoradiotherapy (nedaplatin (CDGP)/5-fluorouracil (5-FU) total 6 course+60 Gy). Afterwards, lymph nodes recurred, and two courses of CDGP/vindesine were given. Then, the primary lesion showed a complete response (CR), and lymph nodes a partial response (PR). In December, 2004, paraesophageal lymph nodes were enlarged to the size of 7 cm. On admission, because of renal disturbance and dementia with advanced age, we chose chemotherapy with TS-1 (100 mg/body/day, three weeks of administration, then two weeks of withdrawal). He had adverse effects of hematotoxicity of grade 3, and non-hematotoxicity of grade 1. He received 6 courses of this regimen and eventually showed CR. Serum SCC was decreased from 4.7 ng/mL to 0.9 ng/mL. At present,the lesions have not recurred during the follow-up for 18 months.

• Authors: Takako Watanabe, Takayuki Chinen, Norishige Nakachi, Manabu Nakamoto, Nobufumi Uchima, Tetsuo Hirata, Akira Hokama, Nagisa Kinjo, Fukunori Kinjo, Jiro Fujita
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 34 Issue 3 Pg. 419-22 (Mar 2007) ISSN: 0385-0684 [Print] Japan
• PMID: 17353634 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Drug Combinations
• S 1 (combination)
• Tegafur
• Oxonic Acid

Topics

• Aged, 80 and over
• Antimetabolites, Antineoplastic (therapeutic use)
• Carcinoma, Squamous Cell (drug therapy, radiotherapy, secondary)
• Combined Modality Therapy
• Drug Administration Schedule
• Drug Combinations
• Esophageal Neoplasms (drug therapy, pathology, radiotherapy)
• Humans
• Lymph Nodes (pathology)
• Lymphatic Metastasis
• Male
• Oxonic Acid (therapeutic use)
• Quality of Life
• Remission Induction
• Tegafur (therapeutic use)